Literature DB >> 27816314

A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS.

Takayo Murase1, Mai Nampei2, Mitsuru Oka2, Atsushi Miyachi2, Takashi Nakamura2.   

Abstract

Associations between elevated plasma xanthine oxidoreductase (XOR) activity and various pathologies have been widely reported. However, it has been difficult to accurately measure human plasma XOR activity because the XOR activity of humans is lower than that of animals such as mouse. We developed a highly sensitive assay for XOR activity utilizing a combination of [13C2,15N2] xanthine and liquid chromatography/triple quadrupole mass spectrometry. In the present study, we established and validated a novel human plasma XOR activity assay utilizing this technique. The calibration curve of [13C2,15N2]uric acid showed linearity over the range of 4-4000nM (r2>0.995) with a lower limit of quantitation of 4nM which corresponds to an XOR activity of 6.67pmol/h/mL plasma. Intra- and inter-assay coefficients of variation of pooled human plasma XOR activity were 6.5% and 9.1%, respectively. Plasma XOR activities of 20 healthy volunteers ranged from 32.8 to 227pmol/h/mL (mean±SD=89.1±55.1, n=20), which correlated with alanine transaminase (r=0.827), aspartate transaminase (r=0.487), and uric acid (r=0.502). The established assay is expected to be useful for investigating the function of XOR and the effect of its inhibitors in various diseases.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Human plasma; Mass spectrometry; Stable isotope labeled substrate; Xanthine oxidoreductase

Mesh:

Substances:

Year:  2016        PMID: 27816314     DOI: 10.1016/j.jchromb.2016.10.033

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  26 in total

1.  Intensive uric acid-lowering therapy in CKD patients: the protocol for a randomized controlled trial.

Authors:  Masato Kasahara; Yoshihiro Kuwabara; Toshiki Moriyama; Kazuaki Tanabe; Noriko Satoh-Asahara; Tomohiro Katsuya; Shinya Hiramitsu; Hidetaka Shimada; Tosiya Sato; Yoshihiko Saito; Takahiko Nakagawa
Journal:  Clin Exp Nephrol       Date:  2019-11-15       Impact factor: 2.801

Review 2.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

3.  Possible role of insulin resistance in activation of plasma xanthine oxidoreductase in health check-up examinees.

Authors:  Masafumi Kurajoh; Shinya Fukumoto; Seigo Akari; Takayo Murase; Takashi Nakamura; Kanae Takahashi; Hisako Yoshida; Shinya Nakatani; Akihiro Tsuda; Tomoaki Morioka; Katsuhito Mori; Yasuo Imanishi; Kazuto Hirata; Masanori Emoto
Journal:  Sci Rep       Date:  2022-06-18       Impact factor: 4.996

4.  Xanthine oxidoreductase activity is correlated with hepatic steatosis.

Authors:  Chisako Yagi; Yoshiki Kusunoki; Taku Tsunoda; Takayo Murase; Takashi Nakamura; Keiko Osugi; Mana Ohigashi; Akiko Morimoto; Akio Miyoshi; Miki Kakutani-Hatayama; Kae Kosaka-Hamamoto; Manabu Kadoya; Kosuke Konishi; Takuhito Shoji; Hidenori Koyama
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

5.  Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm.

Authors:  Ken Watanabe; Tetsuro Shishido; Yoichiro Otaki; Tetsu Watanabe; Takayuki Sugai; Taku Toshima; Tetsuya Takahashi; Miyuki Yokoyama; Daisuke Kinoshita; Takayo Murase; Takashi Nakamura; Masahiro Wanezaki; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; So Yamauchi; Tamon Yamanaka; Takuya Miyamoto; Isao Kubota; Masafumi Watanabe
Journal:  Heart Vessels       Date:  2018-06-23       Impact factor: 2.037

6.  Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.

Authors:  Yuki Fujimura; Yohei Yamauchi; Takayo Murase; Takashi Nakamura; Shu-Ichi Fujita; Tomohiro Fujisaka; Takahide Ito; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

7.  Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.

Authors:  Ayumi Nakatani; Shinya Nakatani; Eiji Ishimura; Takayo Murase; Takashi Nakamura; Mari Sakura; Yu Tateishi; Akihiro Tsuda; Masafumi Kurajoh; Katsuhito Mori; Masanori Emoto; Masaaki Inaba
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

8.  Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction.

Authors:  Ken Watanabe; Tetsu Watanabe; Yoichiro Otaki; Tetsuro Shishido; Takayo Murase; Takashi Nakamura; Shigehiko Kato; Harutoshi Tamura; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Masafumi Watanabe
Journal:  ESC Heart Fail       Date:  2020-05-20

9.  Differential regulation of hypoxanthine and xanthine by obesity in a general population.

Authors:  Masato Furuhashi; Masayuki Koyama; Yukimura Higashiura; Takayo Murase; Takashi Nakamura; Megumi Matsumoto; Akiko Sakai; Hirofumi Ohnishi; Marenao Tanaka; Shigeyuki Saitoh; Norihito Moniwa; Kazuaki Shimamoto; Tetsuji Miura
Journal:  J Diabetes Investig       Date:  2020-02-09       Impact factor: 4.232

10.  Habitual exercise decreases plasma xanthine oxidoreductase activity in middle-aged and older women.

Authors:  Keisei Kosaki; Atsuko Kamijo-Ikemori; Takeshi Sugaya; Koichiro Tanahashi; Nobuhiko Akazawa; Chihiro Hibi; Takashi Nakamura; Takayo Murase; Kenjiro Kimura; Yugo Shibagaki; Seiji Maeda
Journal:  J Clin Biochem Nutr       Date:  2018-03-30       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.